Human Vaccines & Immunotherapeutics (Nov 2021)

Participating in a vaccine trial for COVID-19 in Senegal: trust and information

  • V. Ridde,
  • M. F. Ba,
  • I. Gaye,
  • A. I. Diallo,
  • E. Bonnet,
  • A. Faye

DOI
https://doi.org/10.1080/21645515.2021.1951097
Journal volume & issue
Vol. 17, no. 11
pp. 3907 – 3912

Abstract

Read online

This research aims to understand the level and determinants of people’s willingness to participate in a vaccine trial for COVID-19 in Senegal. We conducted a telephone survey among a marginal quota sample of 607 people over 18 years of age. Only 44.3% of the participants wanted to participate in a vaccine trial for COVID-19, with females intending to participate more than males (AOR = 1.82, 95% CI [1.22–2.72]). Participants who intended to be vaccinated against COVID-19 (AOR = 6.48, 95% CI [4.12–10.4]) and who thought that being infected with the coronavirus would have a significant impact on their health (AOR = 2.34, 95% CI [1.57, 3.51]) were more likely to agree to take part in the COVID-19 vaccine trial. Confidence in the vaccine, health personnel, and the government in the fight against the pandemic are key factors in participants’ willingness to participate in a vaccine trial in Senegal.

Keywords